medicines that address the fundamental biologic pathways critical to tumor initiation growth metastases and recurrence . we are leveraging our understanding of cancer stem cell pathways and immuno oncology targets to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer . for cancer patients clinical trials are essential to obtain the data required for regulatory approval in order to make new medicines broadly available to patients and their prescribing physicians . oncomed is currently conducting numerous clinical trials of our therapeutic candidates . to participate in one of our ongoing clinical trials contact the oncomed clinical trial matching service at 1 866 914 7347 usa or oncomed emergingmed.com . press release archives latest presentations october 2016 european society of medical oncology esmo 2016 congress vantictumab phase 1b pancreatic cancer esmo 2016 ipafricept phase 1b pancreatic cancer esmo 2016 june 2016 american society of clinical oncology asco annual meeting ipafricept phase 1b ovarian cancer asco 2016 vantictumab phase 1b breast cancer asco 2016 demcizumab phase 1b nsclc asco 2016 tarextumab phase 1b sclc asco 2016 home site map careers contact us 2016 oncomed pharmaceuticals inc. all rights reserved .